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Background: Transforming growth factor (TGF)-β is a potent immunosuppressive cytokine necessary for cancer
growth. Animal and human studies have shown that pharmacologic inhibition of TGF-β slows the growth rate of
established tumors and occasionally eradicates them altogether. We observed, paradoxically, that inhibiting TGF-β
before exposing animals to tumor cells increases tumor growth kinetics. We hypothesized that TGF-β is necessary
for the anti-tumor effects of cytotoxic CD8+ T lymphocytes (CTLs) during the early stages of tumor initiation.
Methods: BALB/c mice were pretreated with a blocking soluble TGF-β receptor (sTGF-βR, TGF-β-blockade group,
n=20) or IgG2a (Control group, n=20) before tumor inoculation. Tumor size was followed for 6 weeks. In vivo
lymphocyte assays and depletion experiments were then performed to investigate the immunological basis of our
results. Lastly, animals were pretreated with either sTGF-βR (n=6) or IgG2a (n=6) prior to immunization with an
adenoviral vector encoding the human papillomavirus E7 gene (Ad.E7). One week later, flow cytometry was utilized
to measure the number of splenic E7-specific CD8+ T cells.
Results: Inhibition of TGF-β before the injection of tumor cells resulted in significantly larger average tumor
volumes on days 11, 17, 22, 26 and 32 post tumor-inoculation (p < 0.05). This effect was due to the inhibition of
CTLs, as it was not present in mice with severe combined immunodeficiency (SCID) or those depleted of CD8+ T
cells. Furthermore, pretreatment with sTGF-βR inhibited tumor-specific CTL activity in a Winn Assay. Tumors grew to
a much larger size when mixed with CD8+ T cells from mice pretreated with sTGF-βR than when mixed with CD8+
T cells from mice in the control group: 96 mm3 vs. 22.5 mm3, respectively (p < 0.05). In addition, fewer CD8+ T cells
were generated in Ad.E7-immunized mice pretreated with sTGF-βR than in mice from the control group: 0.6% total
CD8+ T cells vs. 1.9%, respectively (p < 0.05).
Conclusions: These studies provide the first in vivo evidence that TGF-β may be necessary for anti-tumor immune
responses in certain cancers. This finding has important implications for our understanding of anti-tumor immune
responses, the role of TGF-β in the immune system, and the future development of TGF-β inhibiting drugs.
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Transforming growth factor (TGF)-β is a multifunctional
cytokine that is capable of either stimulating or inhi-
biting growth and differentiation of a wide range of cell
types, including many of those in the immune system
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distribution, and reproduction in any mediumis important to both basic science and translational
medicine [4-6].
TGF-β functions primarily as an immunosuppressive
cytokine in the tumor microenvironment due to its abil-
ity to interfere with the generation, expansion, and func-
tion of anti-tumor immune cells [2-4,7]. In a number of
in vitro and ex vivo studies, TGF-β has been associated
with the suppression of growth and/or activity of T cells
[8-12], NK cells [6,13], and dendritic cells [14-16]. The
current in vivo evidence further supports this hypothesis;
using a number of approaches that include anti-TGF-βntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[6,17], translational investigators have consistently re-
ported that the blockade of TGF-β is therapeutically use-
ful in a number of murine tumor systems, including
renal cell cancer [18], melanoma [19], hepatocellular car-
cinoma [20], and glioma [21].Figure 1 TGF-β signaling pathway. Panel A: unimpeded TGF-β signaling
dimerization. 2. TGF-β type I (TGF-βRI) receptor recruitment. 3. TGF-βRI pho
Co-SMAD4 binding. 7. Translocation to the nucleus to activate or repress ta
Ligand does not bind TGF-βRII. 2. TGF-βRI is not recruited, phosphorylated,
phosphorylation of SMAD proteins.Our group previously reported similar anti-tumor ef-
fects after administering a soluble type II TGF-β recep-
tor (sTGF-βR) that binds and neutralizes TGF-β1 and
TGF-β3 in a murine model of established mesothelioma
tumors (Figure 1). In that study, we found that tumor
inhibition by sTGF-βR was due to enhanced activity ofpathway: 1. Ligand binding induces TGF-β receptor type II (TGF-βRII)
sphorylation and activation. 4. SMAD phosphorylation by TGF-βRI. 5.
rget genes. Panel B: sTGF-βR-mediated inhibition of TGF-β signaling. 1.
and activated. 3. Downstream effect is inhibition of TGF-βRII mediated
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In an attempt to augment the anti-tumor effects of TGF-
β-blockade, we also administered sTGF-βR to mice prior
to the injection of various cancer cell lines, including the
mesothelioma cell line AB12. We observed, paradoxically,
that the administration of sTGF-βR prior to injection of
cancer cells resulted in an increased growth rate of AB12
tumors.
The purpose of this study is to further characterize the
role of TGF-β-inhibition in tumorigenesis. The findings
of these studies have important implications for our
overall understanding of the generation of anti-tumor
immune responses, the role of TGF-β in the immune
system, and the future use and development of drugs
that inhibit TGF-β.Methods
Study animals
Pathogen-free female BALB/c and C57BL/6 mice (6–8 weeks
old; weight ~20-25 g) were purchased from Taconic
Labs (Germantown, NY). CB-17 SCID mice (6–8 weeks
old; weight ~20-25 g) were bred at the Wistar Institute
(Philadelphia, PA). All mice were maintained in a
pathogen-free animal facility for at least 1 week before
each experiment. The animal use committees of the
Wistar Institute and University of Pennsylvania ap-
proved all protocols in compliance with the Guide for
the Care and Use of Laboratory Animals.Cell lines
Four murine tumor cell lines were investigated in this
study: the AB12 and AB-1 mesothelioma cell lines, the
TC-1 non-small-cell lung carcinoma cell line, and the
L1C2 bronchoalveolar carcinoma cell line. The non-
malignant mink lung epithelial cells (MLECs) were also
investigated. The AB12 and AB-1 cell lines were
obtained from Dr. Bruce Robinson [23]. These lines were
derived in BALB/c mice and grow well as flank tumors
in this model [24]. The ability of these lines to secrete
TGF-β spontaneously in culture has been studied in de-
tail [25]. AB12 cells secrete large amounts of TGF-β
(462 pmol/106 cells/24 hours), mostly in its latent form.
AB-1 cells, on the other hand, do not secrete significant
quantities of TGF-β [25]. The TC-1 cell line was gener-
ated by transduction of C57BL/6 primary lung epithelial
cells with a retroviral vector expressing HPV16 E6/E7
plus a retrovirus expressing activated c-Ha-ras [26]. This
line is highly tumorigenic in C57BL/6 mice and grows
well as flank tumors in this model. The L1C2 cell line,
obtained from the American Type Culture Collection
(Rockville, MD), is highly tumorigenic in BALB/c mice
and grows well as flank tumors in this model. MLECs,
previously transfected with a plasminogen activatorinhibitor-1 (PAI-1) promoter-luciferase construct, were
obtained from Dr. Daniel Rifkin [27].
AB12, AB-1, L1C2, and MLECs were cultured and
maintained in high glucose Dulbecco’s modified Eagle’s
medium (DMEM; Mediatech, Washington DC) sup-
plemented with 10% fetal bovine serum (FBS; Georgia
Biotechnology, Atlanta GA), 100 units/mL penicillin,
100 μg/mL streptomycin, and 2 mM glutamine. TC-1
was cultured in in RPMI 1640 (Life Technologies, Inc.)
supplemented with 10% FBS, 100 units/mL penicillin,
100 μg/mL streptomycin, and 2 mM glutamine. All cell
lines were regularly tested and maintained negative for
Mycoplasma species.
Quantitative TGF-β bioassay
TGF-β production by the tumor cell lines was quantified
using a highly sensitive and specific, nonradioactive, bio-
assay [27]. This bioassay is based on the ability of TGF-β
to induce PAI-1 expression. Briefly, MLECs stably trans-
fected with a construct containing the human PAI-1
promoter fused to the firefly luciferase reporter gene
were suspended in DMEM containing 10% FBS and
seeded in 96-well plates at a density of 1.6×104 cells per
well. Samples and standards (human platelet-derived
TGF-β1 protein; BD Biosciences PharMingen, San
Diego, CA) were added in triplicate to the plate of
MLECs and incubated for 16 hours at 37°C in a 5% CO2
incubator. Cells were then lysed with 1x cell-lysis buffer
(Analytical Luminescence, Promega, Madison, WI) and
the lysates were transferred to a 96-well plate. Both
substrate A and substrate B (Analytical Luminescence,
Promega) were then added to the samples. Luciferase
activity (a proxy for quantity of TGF-β in the sample)
was measured using an ML1000 luminometer (Dynatech
Laboratories Inc., Alexandria, VA) and reported as rela-
tive light units (RLU).
Soluble TGF-β inhibitor
The soluble recombinant murine TGF-β type II-murine
Fc: IgG2a chimeric protein (sTGF-βR) has previously
been described [22,28]. This chimeric protein binds and
inhibits TGF-β1 and TGF-β3 in the 1 nM range and has
a half-life in mouse plasma of 14 days. Previous studies
have shown biological effects at 1 mg/kg [28], 2 mg/kg
[29], and 5 mg/kg [30]. Based on these reports, we
injected sTGF-βR at a concentration of 1.0 mg/kg in all
of our experiments. Murine IgG2a antibody was used as
a control and injected at the same concentration. The
use of murine IgG2a as a control has been described in
previous studies [29,31].
Animal tumor models
To confirm the effect of sTGF-βR on established tumors
[22], we injected BALB/c mice in 1 flank with 1×106
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sTGF-βR (TGF-β-blockade group, n=5) or mouse IgG2a
(Control group, n=5) when the tumors reached a min-
imal volume of 100 mm3 (approximately 10 days after
tumor cell-inoculation). Animals in the TGF-β-blockade
group received 1 intraperitoneal (IP) injection of sTGF-
βR, once every 3 days, for a total of 6 doses (a 16-day
course). Control animals received murine IgG2a accor-
ding to the same schedule. We then followed tumor bur-
den with serial estimates of tumor volume.
To test the efficacy of pretreatment with sTGF-βR, we
administered sTGF-βR or IgG2a 2 days before inocula-
tion of 1×106 AB12, AB-1, L1C2, or TC-1 tumor cells
into the flank of each animal. The TGF-β-blockade group
received 1 IP injection of sTGF-βR, once every 3 days, for
a total of 3 doses (a 7-day course). The control group re-
ceived murine IgG2a according to the same schedule. We
then followed tumor burden with serial estimates of
tumor volume. As part of our investigation into the basis
of our results, this protocol was subsequently implemen-
ted in SCID animals using AB12 cells.
Lastly, we created a reproducible animal model of
metastatic disease to study sTGF-βR in this context.
First, we injected 1×106 AB12 tumor cells into the right
flank of animals. When the tumors reached a minimal
volume of 100 mm3, we initiated treatment with sTGF-
βR or IgG2a: animals received 1 injection, once every
3 days. After 3 doses of either sTGF-βR or IgG2a, 1×106
AB12 cells were inoculated into the opposite flank, thus
modeling a “metastatic focus”. After tumor re-challenge,
3 additional doses of sTGF-βR or IgG2a were adminis-
tered. We then followed tumor burden in the primary
and secondary inoculation sites with serial estimates of
tumor volume.
In all instances, tumor volume was calculated ac-
cording to the formula (π*long axis*short axis*short
axis)/6, as described previously [22]. We measured
tumor volume at least twice weekly. Unless otherwise
mentioned, each control or experimental group had a
minimum of 5 mice. Each experiment was repeated at
least once.
Flow cytometry on tumor-infiltrating lymphocytes and
lymphocytes in the tumor-draining lymph nodes
To study tumor-infiltrating lymphocytes (TILs) and lym-
phocytes in the tumor-draining lymph nodes (TDLNs),
we compared 3 groups: 1 non tumor-bearing group
(Naïve group, n=9) and 2 groups of tumor-bearing ani-
mals (Control group, n=9 and TGF-β-blockade group,
n=9). The naïve group consisted of BALB/c mice that re-
ceived a one-time IP injection of BD Matrigel™ matrix
(BD Biosciences, Bedford, MA) without tumor cells into
both flanks. The control group consisted of BALB/c
mice that were injected with 1x106 AB12 cells in 250 μLof serum-free DMEM media mixed with 250 μL of BD
Matrigel™ matrix into both flanks. Two days before
tumor cell-inoculation and once every 3 days thereafter,
for a total of 3 doses, these mice received IP injections
of IgG2a (Day −2, Day 1, and Day 4). The TGF-β-block-
ade group consisted of BALB/c mice that were injected
with 1×106 AB12 cells in 250 μL of serum free DMEM
media mixed with 250 μL of BD Matrigel™ matrix into
both flanks. Two days before tumor cell-inoculation and
once every 3 days thereafter, for a total of 3 doses, these
mice received IP injections of sTGF-βR (Day −2, Day 1,
and Day 4).
Two, 4, and 7 days after tumor cell-inoculation, tu-
mors and bilateral inguinal lymph nodes from both the
control (n=3) and TGF-β-blockade (n=3) groups were
harvested. Single-cell suspensions were generated by
mincing these tissues on ice and subsequently filtering
them through a 70μm BD Falcon™ cell strainer (BD Bio-
sciences Discovery Labware, Bedford, MA). These popu-
lations were then stained with the following antibodies:
allophycocyanin (APC) conjugated to rat anti-mouse
CD45 or CD8a (BD Biosciences PharMingen, San Diego,
CA), fluorescein isothiocyanate (FITC) conjugated to rat
anti-mouse CD4, CD11c (BD Biosciences PharMingen,
San Diego, CA), or MHC class I (34-1-2s; eBioscience,
San Diego, CA), and phycoerythrin (PE) conjugated to
rat anti-mouse CD8a, CD11c, CD86 (BD Biosciences
PharMingen, San Diego, CA), or MHC class II (M5/
114.15.2; eBioscience). We then used flow cytometry to
analyze these populations (FACScalibur, Becton-Dickinson,
Mountain View, CA).
Of note, the rationale for inoculation of AB12 tumor
cells in a Matrigel™ matrix for this experiment was based
on the difficulty of generating single cells suspensions
from 2-day old tumors.
Animal vaccine models
To determine if TGF-β-inhibition affects the ability of
mice to generate antigen-specific CD8+ T cells, we stud-
ied the effect of pretreatment with sTGF-βR in animals
immunized against the human papillomavirus E7 protein
using an adenoviral vaccine (Ad.E7). First, 6-to-8 week-
old female C57BL/6 animals were treated with either
sTGF-βR or IgG2a. Two days later, these animals were
immunized with Ad.E7 via subcutaneous injection of
1×109 plaque-forming units (pfu), as previously described
[32,33]. Seven days after immunization, splenocytes were
isolated from each group and analyzed by flow cytometry
to establish the percentage of E7-specific CD8+ T cells
(as determined by tetramer binding).
To determine if TGF-β-inhibition affects the period of
viability of established antigen-specific CD8+ T cells, 6-
to-8 week-old female C57BL/6 mice were immunized with
1×109 pfu of Ad.E7 and treated 7 days later with either
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after immunization), splenocytes from each group (n=3)
were analyzed by flow cytometry to establish the percent-
age of E7-specific CD8+ T cells (as determined by tetramer
binding).
Unless otherwise mentioned, each control group or
experimental group had a minimum of 3 mice. Each
experiment was repeated at least once.
Analysis of E7-specific CD8+ T cells by flow cytometry
Tetramer staining of spleen cells was performed as pre-
viously described [34]. Single cell suspensions were gen-
erated by filtering spleens through a 70 μm BD Falcon™
cell strainer and then incubating the isolated cells for 15
minutes with BD PharM Lyse™, an ammonium chloride-
based red blood cell-lysing reagent (BD Biosciences
PharMingen, San Diego, CA). The remaining viable cells
were incubated with anti-CD16 mAb (eBioscience, San
Diego, CA) for 30 minutes to block non-specific binding
of spleen cells to the Fc portion of test-antibody. Then,
the spleen cells were stained FITC-conjugated anti-
CD8a antibody (BD Biosciences PharMingen) and APC-
conjugated E7 tetramer for 30 minutes and 1.5 hours,
respectively.
APC-labeled H-2Db tetramers loaded with E7 peptide
(RAHYNIVTF) were obtained from the National Institute
of Allergy and Infectious Diseases (eNIAID, Bethesda,
MD) tetramer core. Flow cytometry was performed using
a DakoCytomation CyAn (DakoCytomation, Fort Collins,
CO).
In Vivo depletion of CD8+ T cells
To deplete CD8+ T cells prior to, and during, treatments
with sTGF-βR or IgG2a in our AB12 tumor model, mice
received 200 μg IP injections of monoclonal antibody
purified from the anti-CD8 hybridoma 53–6.7 (obtained
from the American Type Culture Collection). Mice re-
ceived injections both 1 and 3 days prior to inoculation
with AB12 tumor cells. Thereafter, a maintenance dose
was administered once every 7 days throughout the ex-
perimental period to ensure continued depletion. CD8+
T cell depletion was confirmed by flow cytometric ana-
lysis of spleen cells (preparation described above) at the
time of tumor injection and weekly thereafter.
Evaluation of effector function (Winn Assay)
We performed Winn Assays as previously described
[35]. This assay allows for assessment of anti-tumor ac-
tivity of immune effector cells in vivo without the need
for ex vivo stimulation. We first prepared a single-cell
suspension of splenocytes as described above. Then,
CD8+ T cells were isolated from this suspension using
the MACs system (Miltenyi Biotec, Auburn, CA). This
cell population contained greater than 90% CD8+ T cellsas determined by flow cytometry (data not shown). The
CD8+ T cell-enriched populations from non tumor-
bearing (naïve), IgG2a-pretreated animals (control), or
sTGF-βR-pretreated animals (TGF-β-blockade) were
admixed with viable AB12 tumor cells at a ratio of 3
purified CD8+ T cells per 1 tumor cell. This ratio has
previously been determined to be optimal for detecting
positive and negative effects [36]. This mixture was then
inoculated subcutaneously (SC) into the flanks of naïve
BALB/c mice. Each mouse thus received a total of
0.5×106 tumor cells and 1.5×106 CD8+ T cells. Tumor
growth was measured after 1 week and expressed as the
mean ± standard error of the mean. Each group contained
at least 5 mice unless otherwise stated.
Statistical analysis
We implemented unpaired Student’s t-tests to compare
differences in continuous variables between control and
experimental groups. Analysis of variance (ANOVA)
with post-hoc testing was used for multiple comparisons.
We considered differences statistically significant when
the p-value was less than 0.05. Statistical analysis was
conducted using the StatView 5.0 for Windows program
(Abacus Concepts Inc., Berkeley, CA).
Results
AB12 and TC-1 cells produce a large amount of TGF-β
To determine the level of TGF-β production by the mur-
ine cancer cell lines under investigation, we measured
soluble TGF-β by the quantitative bioassay described
above. AB12 and TC-1 cell lines produced more TGF-β
(277.3 pg/mL and 263.3 pg/mL, respectively) than AB-1
and L1C2 (88.9 pg/mL and 92.3 pg/mL, respectively).
The administration of sTGF-βR to animals with
established AB12 tumors inhibits tumor growth, while
treatment before AB12 inoculation stimulates tumor
growth
Previous studies have shown that the administration of
sTGF-βR significantly decreases the growth of esta-
blished AB12 tumors [22]. We conducted a similar ex-
periment to confirm these findings. As expected, the
administration of sTGF-βR into mice with established
AB12 tumors resulted in significantly smaller tumors
compared to control animals receiving IgG2a on days 25
(110 mm3 vs. 345 mm3), 32 (275 mm3 vs. 1165 mm3),
and 37 (400 mm3 vs. 1675 mm3) post tumor-inoculation
(p < 0.05) (Figure 2A). However, the pretreatment of ani-
mals with sTGF-βR, before AB12 inoculation, resulted in
increased tumor growth at multiple time points com-
pared to control animals: AB12 tumors were signifi-
cantly larger on days 11 (305 mm3 vs. 185 mm3), 17
Figure 2 The effects of sTGF-βR on tumor growth according to timing of administration relative to tumor-challenge, animal model,
and murine lung cancer cell line. In all graphs, tumor volume was calculated by the formula (π*long axis*short axis*short axis)/6 and displayed
as mean volume (mm3). Error bars represent standard error of the mean (SEM). IgG2a (control) and sTGF-βR were administered according to
specific schedules. Animals with small (150 mm3), established tumors (Graph A) received IP injections of IgG2a (control) or sTGF-βR, once every
3 days, for a total of 6 doses. Pretreatment animals (Graphs B-F) received IP injections of IgG2a (control) or sTGF-βR two days before tumor
cell-inoculation, and once every 3 days thereafter, for a total of 3 doses. (A). AB12 (established tumors), BALB/c animals (n=5). Established AB12
tumors in animals treated with sTGF-βR were significantly smaller than tumors in control animals treated with IgG2a at multiple time points
(* = p < 0.05). (B). L1C2 (pretreatment), BALB/c animals (n=5). L1C2 tumors in animals pretreated with sTGF-βR were significantly smaller than
tumor in control animals pretreated with IgG2a at multiple time points (* = p < 0.05). (C). TC-1 (pretreatment), C57BL/6 animals (n=5). TC-1
tumors in animals pretreated with sTGF-βR were significantly smaller than tumors in control animals pretreated with IgG2a at one time point
(* = p < 0.05). (D). AB-1 (pretreatment), BALB/c animals (n=5). No significant difference in AB-1 tumor size was evident between control animals
pretreated with IgG2a and animals pretreated with sTGF-βR (p > 0.05). (E). AB12 (pretreatment), BALB/c animals (n=5). AB12 tumors in animals
pretreated with sTGF-βR were significantly larger than tumors in control animals pretreated with IgG2a at multiple time points (* = p < 0.05).
(F). AB12 (pretreatment), SCID animals (n=5). No significant difference in AB12 tumor size was evident between control animals that received
IgG2a and animals that received sTGF-βR (p > 0.05).
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(1325 mm3 vs. 880 mm3), and 32 (2500 mm3 vs. 1595
mm3) post tumor-inoculation (p < 0.05) (Figure 2E). In
contrast, the pretreatment of animals with sTGF-βR be-
fore L1C2 or TC-1 inoculation inhibited tumor growth
compared to control animals (Figure 2B and 2C). Pre-
treatment with sTGF-βR before AB1 inoculation had no
effect on tumor growth (Figure 2D). This experiment
was repeated more than 3 times with similar results
(Figure 3A).The increased rate of AB12 tumor growth after pretreatment
with sTGF-βR is abolished in the SCID animal model
Previous reports have suggested that TGF-β acts as a
direct growth-inhibitor of certain cancer cell lines
[37,38]. Neutralization of TGF-β might therefore induce
more rapid growth. However, our lab has shown that
TGF-β-inhibition results in neither direct stimulation
nor inhibition of AB12 cell proliferation in vitro [22]. To
assess the possibility of indirect immunologically-
mediated effects of TGF-β on tumor cell growth, we
Figure 3 The effect of pretreatment with sTGF-βR on AB12 tumor growth in CD8+ T cell-depleted animals. In all graphs, tumor volume
was calculated by the formula (π*long axis*short axis*short axis)/6 and displayed as mean volume (mm3). Error bars represent standard error of
the mean (SEM). (A). Intact, non CD8+ T cell-depleted animals. Two days before tumor cell-inoculation and once every 3 days thereafter (for a
total of 3 doses), groups of mice (n=5) received IP injections of IgG2a (control) or sTGF-βR (TGF-β-blockade). Tumor volume at 17 days post
tumor cell-inoculation is shown. Tumors in mice pretreated with sTGF-βR were significantly larger than tumors in control animals pretreated with
IgG2a (* = p < 0.05). (B). CD8+ T cell-depleted animals. Two days before tumor cell-inoculation and once every 3 days thereafter (for a total of 3
doses), groups of CD8+ T cell-depleted mice (n=5) received IP injections of IgG2a (control) or sTGF-βR. Tumor volume at 17 days post-tumor cell
inoculation is shown. Depletion of CD8+ T cells resulted in larger absolute tumors in both groups. No significant difference in tumor size was
evident between tumors of control animals pretreated with IgG2a and animals pretreated with sTGF-βR (NS = p > 0.05).
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line in the immunodeficient CB-17 SCID animal model
(which lacks B and T lymphocytes). The pretreatment of
SCID mice with sTGF-βR before AB12 inoculation
abolished the augmentation of growth seen in BALB/c
mice (Figure 2F), as tumor growth rates did not differ
between mice pretreated with sTGF-βR and control
mice pretreated with IgG2a. These experiments show
that the increased rate of tumor growth resulting from
pretreatment with sTGF-βR in the BALB/c tumor model
is not the result of neutralizing direct growth-inhibiting
effects of TGF-β; rather, these results support an
immunologically-mediated mechanism that is dependent
on the presence of B and/or T cells.
The increased rate of AB12 tumor growth after
pretreatment with sTGF-βR is abolished in CD8+
T cell-depleted animals
We then designed a lymphocyte-depletion experiment to
further probe the immunologic basis of our findings anddetermine which cells were responsible for this effect. We
depleted CD8+ T cells after finding small numbers of CD4+
T cells in AB12 tumors by flow cytometry (data not
shown). The pretreatment of naïve (non CD8+ T cell-
depleted) BALB/c animals with sTGF-βR resulted in larger
tumors compared to control animals pretreated with IgG2a
(Figure 3A). At day 17, tumors in control mice were
260 mm3 compared to 350 mm3 in animals pretreated with
sTGF-βR, a 34% augmentation of size (p < 0.05). However,
when BALB/c mice were depleted of their CD8+ T cells,
this significant difference in tumor growth rates between
animals pretreated with sTGF-βR or IgG2a disappeared
(Figure 3B). Mean tumor volume at day 17 in the animals
pretreated with sTGF-βR was 550 mm3 compared to
520 mm3 in the control animals. This 5% difference in
tumor growth was not statistically significant (p>0.05).
These results, in combination with the SCID animal exper-
iments, demonstrate that the stimulatory effect on tumor
growth resulting from pretreatment with sTGF-βR relies
on the presence of CD8+ T lymphocytes.
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abolished tumor-specific CTL activity
The more rapid absolute growth of AB12 tumors in
SCID and CD8+ T cell-depleted mice regardless of treat-
ment (Figure 2) suggests that the wild-type BALB/c
animals mount a tumor-specific, although ultimately in-
effective, CD8+ T cell response against the tumor at early
time points. We have previously documented the pres-
ence of anti-tumor CTLs that arise early in the course of
tumor growth and then disappear as the tumors grow to
larger sizes (>500 mm3) using an in vivo tumor
neutralization assay (Winn Assay) [22,39]. In order to
determine if the increased rate of AB12 tumor growth
associated with sTGF-βR pretreatment was dependent
on the inhibition of naturally-occurring endogenous
anti-tumor CTL, we conducted a Winn Assay as
outlined above.
CD8+ T cells from the spleens of non tumor-bearing
(naïve), IgG2a-pretreated animals (control), or sTGF-βR-
pretreated animals (TGF-β-blockade) were mixed with
AB12 cells (in a 3:1 ratio of CD8+ T cell:tumor cell) and
injected into the flanks of different, non tumor-bearing
animals. At the time of CD8+ T cell isolation, average
tumor sizes of the control and TGF-β-blockade groups
were 310 and 370 mm3, respectively (data not shown).
As shown in Figure 4, the mixture of naïve CD8+ T cells
and AB12 cells resulted in tumors that grew to an ave-
rage size of approximately 100 mm3 after 7 days. This isFigure 4 Winn Assays to assess the in vivo activity of anti-tumor CD8
Tumor volume was calculated by the formula (π*long axis*short axis*short
standard error of the mean (SEM). CD8+ T cells were isolated from the sple
IgG2a, or tumor-bearing animals treated with sTGF-βR. These CD8+ T cells
3 CD8+ T cells to 1 AB12 tumor cell. These mixtures were then injected int
allowed to grow for 1 week. Tumors from mixtures of AB12 tumor cells an
size of approximately 100 mm3 (“naïve” group). Tumors from mixtures of A
grew to an average size of approximately 30 mm3 (“control” group), repres
from mixtures of AB12 cells and CD8+ T cells from animals treated with sTG
size than the control group (** = p < 0.05) and to the same degree as the
Error bars represent SEM.the same average size as tumors resulting from the
inoculation of tumor cells alone (i.e., without CD8+ T
cells) (data not shown). In comparison, the mixture of
control CD8+ T cells and AB12 cells resulted in signifi-
cantly smaller tumors (p <0.05). In contrast, the mixture
of TGF-β-blockade CD8+ T cells with AB12 cells re-
sulted in tumors that grew to a much larger average size
than tumors from the AB12/control CD8+ T cell mixture
(p < 0.05) and to the same average size as tumors from
the AB12/naïve CD8+ T cell mixture. These findings
demonstrate that the increased rate of AB12 tumor
growth after pretreatment with sTGF-βR depends on in-
hibition of naturally-occurring endogenous anti-tumor
CTL activity.
Pretreatment with sTGF-βR before tumor challenge
affects neither the migration of DCs nor their expression
of CD86, MHC class I, or MHC class II
We have shown that anti-tumor CTLs develop sponta-
neously in small AB12 tumor-bearing mice and that
these endogenous CTLs are not active when sTGF-βR is
given before AB12 tumor cell-inoculation. Anti-tumor
CTLs develop from naïve CD8+ T cells that are sensi-
tized to tumor antigen when it is presented by antigen-
presenting cells (mainly dendritic cells (DCs)) in TDLNs.
Initial sensitization of CD8+ T cells typically requires 4
steps: migration of DCs into tumor nodules, ingestion
and subsequent internal-processing of apoptotic cancer+ T cells from animals treated with IgG2a (control) or sTGF-βR.
axis)/6 and displayed as mean volume (mm3). Error bars represent
ens of non tumor-bearing animals, tumor-bearing animals treated with
were then mixed with fresh AB12 tumor cells according to a ratio of
o the flanks of naïve BALB/c mice (n=5 per group). Tumors were then
d CD8+ T cells from non tumor-bearing animals grew to an average
B12 tumor cells and CD8+ T cells from animals treated with IgG2a
enting a 68% inhibition of growth (* = p < 0.01). However, tumors
F-βR (“TGF-β-blockade” group) grew to a significantly larger average
naïve group (NS = p > 0.05). Displayed values are mean volume (mm3).
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in both MHC class I and class II complex clefts (by acti-
vated DCs), and migration of the activated DCs into
TDLNs where T cell-sensitization occurs. In order to de-
termine if pretreatment with sTGF-βR affects anti-
tumor CTLs indirectly through interruption of these 4
steps, we used flow cytometry to study the effect of pre-
treatment with sTGF-βR on both the number of DCs
and the expression of DC-activation markers (CD86,
MHC class I and II) in the tumor and TDLNs.
The total number of lymphocytes and DCs in TDLNs
of mice injected with tumor cells were significantly
increased at day 2, 4 and 7 compared to naïve non
tumor-bearing mice (Figure 5A). However, no significant
differences in the total number of DCs, CD8+ T cells, or
CD4+ T cells in TDLNs were found between tumor-
bearing mice pretreated with IgG2a and tumor-bearing
mice pretreated with sTGF-βR. Furthermore, no signifi-
cant differences in the mean fluorescence intensities
(MFIs) of CD86, MHC class I, or MHC class II in DCs
were found between tumor-bearing mice pretreated
with IgG2a and tumor-bearing mice pretreated with
sTGF-βR.
When we compared tumors between groups, as ex-
pected, the average AB12 tumor weight at day 7 post
tumor cell-inoculation in mice pretreated with sTGF-βR
was significantly greater than the average tumor size in
mice pretreated with IgG2a (data not shown). However,
no significant differences were found in the totalFigure 5 Tumor and tumor-draining lymph node cell counts and mea
total number of lymphocytes and DCs in TDLNs (A) of tumor-bearing mice w
Furthermore, the expression of CD86 on CD11c+ cells was significantly lower
However, no significant differences in the total number of DCs, CD8+ T cells, o
CD11c+ in tumors (B) were found between tumor-bearing mice pretreated w
(* denotes p < 0.05).numbers of tumor-infiltrating CD45+ cells, DCs, or CD8+
T cells between tumor-bearing mice pretreated with
sTGF-βR and tumor-bearing mice pretreated with IgG2a
(Figure 5B). These findings demonstrate that the increased
rate of AB12 tumor growth resulting from pretreatment
with sTGF-βR is not due to an effect on the migration or
activation (assessed by expression levels of CD86 and
MHC class I and II) of DCs.
Administration of sTGF-βR to animals with established
AB12 tumors does not increase the growth rate of
secondary “metastatic” tumors
The inhibition of TGF-β in animals with established tu-
mors reduces tumor growth rates and both augments
and preserves anti-tumor CTL function [22]. In contrast,
data from the present study suggest that the blockade of
TGF-β at the time of tumor initiation inhibits tumor-
specific CTLs and augments tumor growth. Given these
results, we questioned the therapeutic utility of sTGF-βR
in patients who might develop secondary (metastatic) le-
sions. To determine if the blockade of TGF-β, at a time
point after anti-tumor CTLs have been induced, en-
hances secondary tumor growth, we administered sTGF-
βR (TGF-β-blockade) or IgG2a (control) to BALB/c mice
after AB12 tumors had formed but before re-challenge
with a second AB12 “metastatic focus” in the opposite
flank. We then continued treatment with sTGF-βR or
IgG2a after the re-challenge and serially measured then-fluorescence intensities on day 4 post tumor-inoculation. The
ere significantly increased compared to naïve non tumor-bearing mice.
in naïve non tumor-bearing mice compared to tumor-bearing mice.
r CD4+ T cells in TDLNs, or the percentages of CD45+, CD4+, CD8+, or
ith IgG2a and tumor-bearing mice pretreated with sTGF-βR
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shown in Figure 6A, the administration of sTGF-βR sig-
nificantly inhibited the growth of small, established
AB12 tumors compared to IgG2a (p < 0.05 on Day 25,
32, and 36). Furthermore, the administration of sTGF-
βR significantly inhibited the growth of secondary AB12
tumors compared to IgG2a on days 20 (65 mm3 vs.
227 mm3) and 25 (115 mm3 vs. 505 mm3) post tumor-
inoculation (p < 0.05) (Figure 6B). These results demon-
strate that the blockade of TGF-β after anti-tumor CTLs
have been induced does not enhance secondary tumor
growth.Figure 6 The effect of sTGF-βR on secondary flank tumors in a
model of metastatic disease. In all graphs, tumor volume was
calculated by the formula (π*long axis*short axis*short axis)/6
and displayed as mean volume (mm3). Error bars represent
standard error of the mean (SEM). (A). Groups of mice (n=5) bearing
small, established AB12 tumors (150 mm3) received IP injections of
IgG2a (control) or sTGF-βR(TGF-β-blockade), once every 3 days, for a
total of 6 doses (marked by hatched bar). After 3 doses of either
IgG2a or sTGF-βR, 1x106 AB12 cells were inoculated into the
opposite flank to model “metastatic foci”. An arrow shows the time
point when secondary tumor cell injection was performed. Tumor
volume was subsequently measured over time. Established primary
flank tumors in mice treated with sTGF-βR were significantly smaller
than tumors in control animals treated with IgG2a at multiple time
points (* = p < 0.05). (B). The volume (mm3) of secondary flank
tumors was measured for up to 4 weeks post-inoculation. Secondary
tumors in animals treated with sTGF-βR were significantly smaller
than secondary tumors in control animals treated with IgG2a at
multiple time points (* = p < 0.05).Pretreatment with sTGF-βR before immunization with Ad.
E7 inhibits the generation of E7-specific CD8+ T cells
To determine if TGF-β is required to generate antigen-
specific CD8+ T cells, we utilized a previously developed
adenoviral vector that expresses the well-studied viral tumor
antigen human papilloma virus E7 protein (Ad.E7). In this
independent and more quantifiable system, we investigated
how the blockade of endogenous TGF-β, at a time point
before antigen immunization, affected the generation and
maintenance of antigen-specific CD8+ T cells [32,33].
The average percentage of E7-specific CD8+ T cells
among total CD8+ splenocytes of naïve, non-vaccinated
mice is less than 0.5% (see example in Figure 7B). Seven
days after immunization with Ad.E7, in control mice
pretreated with IgG2a, the average percentage of E7-
specific CD8+ T cells among total CD8+ splenocytes was
1.9% (Figure 7A and example in Figure 7B). In contrast,
the average percentage of E7-specific CD8+ T cells
among total CD8+ splenocytes of vaccinated mice
pretreated with sTGF-βR was 0.6%, which was signifi-
cantly lower than the vaccinated control group (p < 0.05)
(Figure 7A with an example in Figure 7B). There was no
significant difference in the number of splenocytes or
percentage of splenocytes that were CD8+ between mice
pretreated with IgG2a or sTGF-βR. These data suggest
that TGF-β is required to generate E7-specific CD8+ T
cells after immunization with Ad.E7.
The administration of sTGF-βR after E7-immunization
prevents the spontaneous loss of E7-specific CD8+ T cells
We then utilized the adenoviral vector system to deter-
mine if sTGF-βR affects the period of viability of
established E7-specific CD8+ T cells. Seven days after
immunization with Ad.E7, we initiated treatment with
either IgG2a or sTGF-βR. At this point in time, before
any further intervention, the average percentage of E7-
specific CD8+ T cells among total CD8+ splenocytes was
1.9% (the Day 7 E7-specific CD8+ T cell percentage).
Seven days after initiating these treatments (14 days after
immunization with Ad.E7), this percentage decreased
significantly to 0.8% in mice treated with IgG2a (p < 0.05)
(Figure 8A) but remained at 1.36% in mice treated with
sTGF-βR, a difference which was not statistically different
from the Day 7 E7-specific CD8+ T cell percentage of 1.9%
(p = 0.14) (Figure 8A). Typical flow cytometry plots, after
staining for CD8 and E7 tetramer, are provided for each
group in Figure 8B. These data suggest that the blockade
of endogenous TGF-β, at a time point after immunization
with Ad.E7, prevents spontaneous, time-dependent loss
of E7-specific CD8+ T cells.
Discussion
Because of its multiple distinct functions in a variety of
experimental models of T cell immunology, it has been
Naïve 
Control IgG2a  TGF- -blockade 






























Figure 7 The effect of pretreatment with sTGF-βR on the generation of E7-specific CD8+ T cells after immunization with Ad.E7. (A).
Groups of mice (n=3) were treated with either IgG2a (control) or sTGF-βR 2 days before immunization with Ad.E7. Seven days after immunization,
splenocytes from these animals were subjected to flow-cytometric analysis using anti-CD8 antibody and E7 tetramer. Displayed values are mean
percentages of E7-tetramer positive CD8+ T cells among total splenic CD8+ T cells. Error bars represent SEM. The percentage of E7-specific CD8+ T
cells in animals treated with sTGF-βR (“TGF-β-blockade”) was significantly less than the percentage of E7-specific CD8+ T cells in control animals
treated with IgG2a (“Control IgG2a”): 0.6% and 1.9%, respectively (* = p < 0.01). (B). Examples of two-color (FITC and APC) flow cytometry dot
plots in the analysis of CD8+ T cells isolated from the groups described in part A. Displayed values are percentages of CD8+ E7 tetramer-positive
cells among total splenic CD8+ T cells. “Naïve” = non-immunized animals; “Control IgG2a/Ad.E7” = animals treated with IgG2a 2 days before
immunization with Ad.E7. “TGF-β-blockade/Ad.E7” = animals treated with sTGF-βR 2 days sbefore immunization with Ad.E7.
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http://www.biomedcentral.com/1471-2172/14/30difficult to develop a clear model of the in vivo roles of
TGF-β [7,40]. There is ample data to support the hy-
pothesis that TGF-β is an immunosuppressive factor. As
summarized previously [3,8,15,16,40], TGF-β has been
reported to (1) inhibit T cell proliferation, CTL gener-
ation, and T cell cytokine production; (2) interfere
withTH1/TH2 differentiation and the differentiation of
naïve T cells towards central memory cells; and (3)
inhibit dendritic cell (DC)-mediated antigen presentation
by inhibiting DCs’ endocytic and phagocytic acti-
vities, preventing DC-maturation, and blocking the
up-regulation of critical DC-associated co-stimulatory
molecules.
In contrast, there are other studies (although fewer)
that have reported that TGF-β exerts stimulatory effects
on human T cells and dendritic cells. There is evidence
that under some conditions, TGF-β can (1) support the
generation of effector cells; (2) augment the develop-
ment of memory and mature T cell populations; (3) co-stimulate the growth and maturation of CD4+ and CD8+
T cells; (4) inhibit the apoptosis of CD4+ T cells;
(5) promote the in vitro development of DCs from
hematopoietic progenitors; and (6) regulate the che-
motaxis of DCs via regulation of chemokine receptor
expression [40-46].
Based on the paradigm that TGF-β is “one of the most
potent immunosuppressors described to date” [4], trans-
lational investigators have tried to inhibit tumor growth
in animal models by blocking TGF-β production, recep-
tor binding, or function. Using a number of approaches
that include anti-TGF-β antibodies, soluble receptors, or
TGF-β-binding proteins [6,17], investigators have con-
sistently reported that blockade of TGF-β is therapeuti-
cally useful in a number of murine tumor systems,
including renal cell cancer [18], melanoma [19], hepato-
cellular carcinoma [20], and glioma [21].
The literature is currently unable to bridge these
seemingly contradictory findings regarding TGF-β in
Day 7 Ad.E7
Day 14 Ad.E7 /  
Control IgG2a


























Figure 8 The effect of treatment with sTGF-βR on established E7-specific CD8+ T cells that were generated by Ad.E7 administration.
(A). Groups of mice were immunized with Ad.E7. Seven days post-immunization, splenocytes were isolated and subjected to flow-cytometric
analysis (“Day 7 E7-specific CD8+ percentage”) using anti-CD8 antibody and E7 tetramer. Displayed values are mean percentages of E7-tetramer
positive CD8+ T cells among total splenic CD8+ T cells. Then, at this time point of 7 days post-immunization, other groups of mice (n=3) were
treated with IgG2a or sTGF-βR. At day 14 post-immunization, splenocytes from these animals were isolated and subjected to flow-cytometric
analysis. The percentage of E7-specific CD8+ T cells from control animals treated with IgG2a on day 14 post-immunization with Ad.E7 (“Day 14
E7-specific CD8+, Control IgG2a”) was significantly less than the Day 7 E7-specific CD8+ percentage: 0.8% vs. 1.9%, respectively (* = p < 0.05).
However, the percentage of E7-specific CD8+ T cells from animals treated with sTGF-βR on day 14 post-immunization with Ad.E7 (“Day 14 E7-specific
CD8+, TGF-β-blockade”) was not significantly different than the Day 7 E7-specific CD8+ percentage (NS, p > 0.05). (B). Examples of two-color
(FITC and APC) flow-cytometry dot plots in the analysis of CD8+ T cells isolated from the groups described in part 6A. Displayed values are
percentages of CD8+ E7 tetramer-positive cells among total splenic CD8+ T cells. “Day 7 Ad.E7” = non-treated animals 7 days after immunization
with Ad.E7. “Day 14 Ad.E7/Control IgG2a” = animals 14 days after immunization with Ad.E7 and 7 days after IgG2a treatment. Day 14 Ad.E7/
TGF-β-blockade = animals 14 days after immunization with Ad.E7 and 7 days after sTGF-βR treatment.
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the experimental models used, the type of stimulus, the
presence of other cytokines, the dose of TGF-β, the dis-
tribution of TGF-β in its latent and active form, the du-
ration of the stimulation, and possibly, the genetic
background of the cell populations studied [40]. Regard-
less of the reasons, since TGF-β blocking agents are cur-
rently being developed for clinical use, it has become
increasingly important to better understand the effects
of TGF-β on in vivo anti-tumor immune cell function.
We observed that blockade of TGF-β with sTGF-βR
before the inoculation of tumor cells (and for 3 doses
afterwards) resulted in significantly enhanced tumor
growth of one particular tumor cell line, the AB12 line
(but not in others). This response was in marked con-
trast to the inhibition of tumor growth associated with
administration of the same TGF-β blocking agent after
the establishment of the same tumor cell line. In thisstudy, we examined the mechanism responsible for the
increased rate of AB12 tumor growth resulting from pre-
treatment with sTGF-βR. We demonstrated that altered
anti-tumor immune responses were responsible for this
augmentation of tumor growth; specifically, administra-
tion of sTGF-βR before tumor cell-inoculation resulted in
the failure to generate active anti-tumor CTLs.
The specific characteristics of the relatively immuno-
genic tumor model used in these studies are important
to understand our findings. Mesotheliomas usually result
from prior asbestos exposure. They are associated with a
high degree of MHC class I expression and TGF-β pro-
duction. Clinically, they respond to some immune-based
therapies. The mouse mesothelioma tumor cells used in
this study are very similar to human tumors. When
AB12 cells are injected into syngeneic BALB/c mice,
their initial growth is quite slow until about 20 days,
at which point their size begins to increase rapidly
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growth phase is due to a partially effective anti-tumor
immune response mediated by endogenous, functionally
active tumor antigen-specific CTLs. We have observed
that AB12 tumors grow much more rapidly in SCID mice
(Figure 2F), in CD8+ T cell-depleted mice (Figure 3B), and
in IFNγ-knockout or IFNγ-neutralized mice (data not
shown). We have also directly examined the ability of
AB12 tumors to generate anti-tumor immune responses.
Within 4–10 days after subcutaneous injection of AB12
tumor cells, we have detected CD8+ T cells in the spleen
that have cytolytic activity [22]. We confirmed the pres-
ence of these spontaneously generated anti-tumor CTLs
in this study (Figure 4) using a Winn assay that demon-
strated markedly inhibited tumor growth when tumor
cells were mixed with CD8+ splenocytes from control
tumor-bearing animals before inoculation into naïve non
tumor-bearing animals. These anti-tumor CTLs persist
until the tumor reaches a size of approximately 400 mm3
(usually about 20 days after injection). At this time, CTL
activity can no longer be detected and tumor growth rate
rapidly increases.
Our experiments indicate that the increased rate of
AB12 tumor growth resulting from pretreatment with
sTGF-βR was due to a loss of this normal, low-level, and
only partially-effective anti-tumor CTL immune re-
sponse. First, the growth-augmenting effects of sTGF-βR
relative to IgG2a were lost in T cell-deficient SCID mice
(Figure 2F) and CD8+ T cell-depleted mice (Figure 3B).
Second, we showed that the inhibition of TGF-β nega-
tively impacts the functionality of CD8+ CTLs, as the
Winn assay (essentially an in vivo test of CD8+ T cell
functionality) demonstrated a reduced anti-tumor re-
sponse with an equivalent number of CD8+ T cells from
mice pretreated with sTGF-βR compared to control ani-
mals pretreated with IgG2a (Figure 4). Together, these
results implicate the inhibition of anti-tumor CD8+
CTLs as central to the augmentation of AB12 tumor
growth associated with sTGF-βR pretreatment.
In addition to our tumor study, we also investigated
the effect of TGF-β-blockade on the generation of active
antigen-specific CTLs against a known viral tumor anti-
gen in an independent and more quantifiable system.
Pretreatment with sTGF-βR, at a time point before
immunization with an adenovirus encoding the HPV E7
protein (Ad.E7), inhibited the generation of E7-specific
CD8+ T cells as compared to control pretreatment with
murine IgG2a. These experiments show that TGF-β is
required for the generation of active CTLs, at least in
models employing AB12 tumor cells or vaccination with
Ad.E7.
Unfortunately, despite further investigation, the mech-
anism by which pretreatment with sTGF-βR inhibits
CTL-activity remains unclear. Initial sensitization ofCD8+ T cells typically requires 4 steps as described
above. We showed that pretreatment with sTGF-βR does
not decrease the activation status or the number of DCs,
CD4+ T cells, or CD8+ T cells in the TDLNs or tumor
beds compared to IgG2a. These data indicate that TGF-
β may not be required for the migration or proliferation
of DCs, CD4+ T cells, or CD8+ T cells or the activation
of DCs. Although studies of expression levels of CD86,
MHC class I, and MHC class II are important to evalu-
ate the activation levels of DCs in anti-tumor immune
responses, other activation markers for DCs might exist,
such as ICAM-1 or B7. It may also be important to test
the expression levels of accessory molecules on T lym-
phocytes, such as LFA-1 or CD28. Thus, the mechanism
by which pretreatment with sTGF-βR stimulates the
growth of tumors in our AB12 tumor model remains
unclear.
Another interesting question relates to the issue of
why sTGF-βR did not inhibit the generation of anti-
tumor CD8+ CTL activity in other tumor models as it
did in the AB12 tumor model. We explored a number of
obvious explanations: low amounts of TGF-β produced,
lack of tumor immunogenicity, or animal strain differ-
ences. With regard to TGF-β production, we know that
AB-1 cells make very little TGF β which could explain
the lack of effect in this cell line. However, the TC-1 cell
line makes sizeable amounts of TGF-β and yet it is still
resistant. We have also studied the L1C2 and TC-1 cell
lines in the past and have shown them to be moderately
or highly immunogenic, similar to the AB12 model, and
able to induce anti-tumor CD8+ T cells [47]. To address
the issue of strain differences, we also studied L1C2
cells, another tumor line that grows in BALB/c mice
(like AB12), and saw no response. We thus have no sim-
ple explanation for the selectivity for our observation.
The tumor microenvironment is a complex ecosystem
which is unique to each tumor model. Given the genetic
modifications required for malignant transformation, it
is likely that a myriad of factors, including various cy-
tokines, chemokines, other soluble factors, and even
cell-bound mediators play significant roles in tumor de-
velopment and in the interaction with the host’s immune
system. The key point is that this stimulation of tumor
growth after early TGF-β inhibition can occur in at least
one animal model and thus should be carefully looked
for in future clinical trials. Additional ongoing research
that identifies the key factors responsible for this effect
will be needed.
Conclusions
In conclusion, this paper provides the first in vivo evi-
dence, to our knowledge, that the blockade of TGF-β
inhibits the initial generation of functionally active anti-
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E7 vaccination. These findings support the novel hy-
pothesis that, at least under some circumstances, TGF-β
is required for the generation of active anti-tumor CTLs.
Given the complexity of the in vivo anti-tumor immune
response, we have not yet defined the step at which
TGF-β-blockade inhibited CTL activation. Although
pretreatment with sTGF-βR may not be involved in the
migration of immune cells (Figure 5), possible mecha-
nisms include inhibition of either antigen presentation
by DCs or other antigen-presenting cells, T cell differenti-
ation, or generation of memory/effector cells. Experiments
to differentiate among these potential mechanisms are in
progress.
The implications of our findings are significant. From
an immunological standpoint, our results support the
complex in vivo functions of TGF-β and suggest a po-
tentially new paradigm for its role in the generation of
CD8+ memory and/or effector cells. Since it is extremely
difficult to model all the variables that factor into an
in vivo immune response, it will be very important to
study the effects of TGF-β manipulation in a variety of
animal models. From a more practical standpoint, these
results may help guide the use of TGF-β inhibitors.
Given our observation that TGF-β is required for anti-
tumor immune responses, along with other data show-
ing that TGF-β-blockade can enhance carcinogenesis
through tumor cell-intrinsic mechanisms [48-50], the
use of TGF-β inhibitors in a chemopreventive mode
should be undertaken with caution. On the other hand,
the use of TGF-β inhibitors in patients with established
tumors might prove very useful. One encouraging find-
ing from our study was that the blockade of TGF-β did
not lead to increased growth rates at secondary (“meta-
static”) sites. These data support the hypothesis that
blockade of TGF-β does not enhance tumor growth after
anti-tumor CTLs have been induced.
We also have evidence from the Ad.E7 model that
TGF-β-blockade promotes the persistence of established
antigen-specific CD8+ T cells that were induced by im-
munization at a time point prior to sTGF-βR administra-
tion (Figure 8B). While the percentage of E7-specific
CD8+ T cells in control animals decreased significantly
1 week after IgG2a administration, the percentage of
E7-specific CD8+ T cells in animals treated with sTGF-
βR remained stable at the same time point. These results
thus support the use of TGF-β-inhibition in patients
with established tumors.
In summary, we present an in vivo tumor model dem-
onstrating that the timing of TGF-β blockade can deter-
mine whether tumor growth is inhibited or enhanced.
These experiments highlight the pleomorphic effects of
TGF-β and emphasize the importance of careful patient-
selection for novel TGF-β inhibitors.Abbreviations
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